SCHEMBL23458593

SCHEMBL23458593

Cc1nc(N(C(=O)OC(C)(C)C)C(=O)OC(C)(C)C)c2ccn(C(=O)OC(C)(C)C)c2n1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BUB1 O43683 1/20 0.34
HSP90AA1 P07900 1/20 0.34
HSP90AB1 P08238 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.32
GPR119 Q8TDV5 2/20 0.32
PIK3CD O00329 1/20 0.32
ABL1 P00519 1/20 0.32
EGFR P00533 1/20 0.32
HCK P08631 1/20 0.32
SRC P12931 1/20 0.32
KDR P35968 1/20 0.32
PIK3CA P42336 1/20 0.32
PIK3CB P42338 1/20 0.32
MTOR P42345 1/20 0.32
PIK3CG P48736 1/20 0.32
EPHB4 P54760 1/20 0.32
PRKDC P78527 1/20 0.32
PI4KB Q9UBF8 1/20 0.32
PDPK1 O15530 1/20 0.32
BCHE P06276 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29838663 1.00 BUB1 (0.34) BUB1HSP90AA1HSP90AB1L3MBTL1GPR119
SCHEMBL23458592 0.90 MEN1 (0.32) PDPK1
SCHEMBL31123801 0.87 BUB1 (0.34) BUB1HSP90AA1HSP90AB1PIK3CDABL1
SCHEMBL31123773 0.87 BUB1 (0.34) BUB1HSP90AA1HSP90AB1PIK3CDABL1
SCHEMBL19714886 0.81 PDPK1 (0.42) BUB1HSP90AA1HSP90AB1GPR119PIK3CD
SCHEMBL18009865 0.81 BUB1 (0.34) BUB1HSP90AA1HSP90AB1L3MBTL1GPR119
SCHEMBL17528555 0.80 HSP90AA1 (0.41) BUB1HSP90AA1HSP90AB1L3MBTL1GPR119
SCHEMBL17528558 0.78 CRHR1 (0.35) BUB1HSP90AA1HSP90AB1EGFRKDR
SCHEMBL21683427 0.77 HSP90AA1 (0.38) BUB1HSP90AA1HSP90AB1PIK3CDABL1
SCHEMBL28914081 0.77 PDPK1 (0.33) PDPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230066014-A1 SUBSTITUTED NUCLEOSIDE ANALOGS AS PRMT5 INHIBITORS LUPIN LIMITED (IN) 2023-03-02 US disclosed
EP-4069698-A1 SUBSTITUTED NUCLEOSIDE ANALOGS AS PRMT5 INHIBITORS Lupin Limited (IN) 2022-10-12 EP disclosed
WO-2021111322-A1 SUBSTITUTED NUCLEOSIDE ANALOGS AS PRMT5 INHIBITORS LUPIN LIMITED (IN) 2021-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230066014-A1 SUBSTITUTED NUCLEOSIDE ANALOGS AS PRMT5 INHIBITORS PRMT5, PRMT1, PRMT3 BUB1 2716/4885HSP90AA1 4751/4885HSP90AB1 4522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.